Drug Delivery

Kelai Pharmaceuticals has struck a deal to collaborate with Double Rainbow Biosciences, positioning it to explore the potential of biosynthetic therapeutics and the pairing of its drug delivery systems and its new partner’s capabilities.

Former Novartis subsidiary Alcon, after targeting the pharmaceutical eye drop scene with a trio of recent drug purchases, is adding another pair of arrows to its ophthalmic quiver. And this time, the company is setting its sights long-distance.

Nearly six months after an FDA rejection, Gilead Sciences’ next-generation, long-acting HIV med lenacapavir has picked up its global-first approval in Europe. But the company still needs to find the first-in-class drug a proper combination partner after a high-profile Merck setback.

This week on "The Top Line," we discuss Novartis’ gene therapy Zolgensma—and the two deaths following treatment. We also hear from AstraZeneca on its strategy to get into the CAR-T space with off-the-shelf cancer cell therapies.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Set a solid foundation for successful scale-up of buffer preparation.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.